A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders; Insomnia
  • Focus Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2008 Results published in The Lancet.
    • 10 Nov 2007 Status changed from in progress to completed.
    • 10 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top